Progress in matrix metalloproteinase research.

By Gillian Murphy, Hideaki Nagase. Molecular Aspects of Medicine, 2008

743 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. (2009, background): “the reader to a number of comprehensive reviews on this topic(4-7) as well as for a review of the general biochemistry of the MMP family.(2,8,9) Based on their”
Matrix metalloproteinases. (2010, background): “MMPs have been implicated in intimal thickening, a repair response to wall damage of large arteries in human atherosclerotic pathologies, as well as in plaque rupture [180].”
Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease. (2018, background): “Other proteinase inhibitors may inhibit MMPs by unclear mechanisms (Murphy and Nagase, 2008).”
The tissue inhibitors of metalloproteinases (TIMPs): An ancient family with structural and functional diversity (2010, background): “The major proteinases involved in ECM catabolism are the matrix metalloproteinases (MMPs), which include collagenases, gelatinases, stromelysins, matrilysins, membrane-type MMPs and others [1] and the ADAMTS (a disintegrin and metalloproteinase with thrombospondin domains) metalloproteinases [2].”
Role of Matrix Metalloproteinases in Angiogenesis and Cancer (2019, methodology): “This means that the activity of MMPs is regulated by a post-translational proteolytic cleavage and endogenous inhibitors (15, 21).”